H.C. Wainwright Starts Lipocine Inc (LPCN) at Buy, PT $25
- Wall Street again marks new highs in post-election run
- Broadcom Ltd. (AVGO) Tops Q4 EPS by 11c
- Restoration Hardware (RH) Tops Q3 EPS by 4c; Guides Well Below the Street
- Unusual 11 Mid-Day Movers 12/8: (COOL) (TLRD) (DRAM) Higher; (SHIP) (OHRP) (MLSS) Lower
- After-Hours Stock Movers 12/08: (FNSR) (AVGO) (GLPG) Higher; (XTLY) (RH) (DLTH) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
H.C. Wainwright initiated coverage on Lipocine Inc (NASDAQ: LPCN) with a Buy rating and a price target of $25.
Analyst Corey Davis said, "Our Lipocine investment thesis hinges on the success of three late-stage orally-formulated steroid products to better compete with current products that are either injectable or topical. LPCN 1021 (brand name Tylando) is a twice-daily oral formulation of testosterone for hypogonadal men (low testosterone), that received a Complete Response Letter on June 29, 2016 and should have clarity as to the path forward this month. LPCN 1111 is a once-daily next generation prodrug of testosterone that announced successful Phase 2b on September 26. LPCN 1107 is an oral version of hydroxyprogesterone for pre-term birth that would compete directly with Makena and is ready to enter Phase 3."
Shares of Lipocine Inc closed at $4.17 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Downgrades Timken (TKR) to Hold
- UPDATE: Stifel Downgrades EMCOR Group (EME) to Hold
- lululemon athletica (LULU): Skeptics Are Quieter - Wedbush
Create E-mail Alert Related CategoriesAnalyst Comments, Hot New Coverage, New Coverage
Related EntitiesH.C. Wainwright
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!